Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Interim Results Of A Pioneering Combination Study In Argentina With More Than 1,000 Participants Confirm The One-shot Sputnik Light Vaccine (The First Component Of The Sputnik V Vaccine) Is An Effective Universal Booster For Vaccines Produced By AstraZeneca, Sinopharm, Moderna And Cansino Inducing Strong Immune Response And Showing High Safety Profile. Combination Of AstraZeneca And Sputnik Light Vaccines Showed High Immunogenicity Results. 2021-10-15 05:26
More community healthcare needed in COVID-19 planning as chronic disease rates pressure hospitals 2021-10-13 05:00
Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease 2021-10-09 03:07
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients 2021-10-04 21:24
Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021 2021-10-04 08:00
Impact Credit Solutions and Bank Central Asia partner to offer financing to the Indonesian healthcare sector 2021-09-30 09:00
Zymo Research Pays it Forward With Their Commitment to Eradicate the COVID-19 Pandemic in India 2021-09-28 14:57
Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy 2021-09-28 08:00
LEAD Horizon: How travelers in Austria gargle against the corona virus 2021-09-27 09:00
Kintor Pharma Announces Brazil's ANVISA Approves Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients 2021-09-26 23:09
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases 2021-09-24 08:47
/C O R R E C T I O N -- pHOXBIO/ 2021-09-24 02:42
Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine 2021-09-23 21:59
BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins 2021-09-23 15:00
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico 2021-09-22 20:00
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest 2021-09-22 18:56
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug 2021-09-22 18:45
The International Standard Proposed by Experts from BMC Medical in Terms of High-flow Respiratory Therapy Equipment Officially Released 2021-09-22 15:00
FII Institute Launches Global Infectious Diseases Index 2021-09-21 23:19
Novavax to Participate in Fireside Chat at Devex @ UNGA 76 2021-09-21 04:46
1 26 27 28 29 30 93